These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29996003)

  • 1. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
    Chartier N; Epstein J; Soudant M; Dahan C; Michaud M; Pittion-Vouyovitch S; Guillemin F; Debouverie M; Mathey G
    Eur J Neurol; 2018 Dec; 25(12):1439-1445. PubMed ID: 29996003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
    Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Le Page E; Leray E; Edan G;
    Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
    Lefort M; Le Corre G; Le Page E; Rizzato C; Le Port D; Michel L; Kerbrat A; Leray E; Edan G
    Rev Neurol (Paris); 2022 Jun; 178(6):569-579. PubMed ID: 35181157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
    Benesova Y; Stourac P; Beranek M; Kadanka Z
    Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
    Le Page E; Deburghgraeve V; Lester MA; Cardiet I; Leray E; Edan G
    J Neurol; 2015; 262(4):1024-34. PubMed ID: 25701008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
    Edan G; Comi G; Le Page E; Leray E; Rocca MA; Filippi M;
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1344-50. PubMed ID: 21436229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
    Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
    Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M
    Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
    BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
    Gonsette RE
    J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.